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Introduction 
Although nationally the amounts of prescribed opioids peaked about eight years ago, opioid overdose 
deaths and related adverse outcomes continue to rise and have emerged as a public health emergency 
in the United States.[2; 3; 5; 12]  Earlier studies demonstrated increased trends in opioid prescribing and 
a concomitant increase in other sedative/stimulant prescription rates paralleled by adverse events, 
particularly hospitalizations and overdose deaths, in various populations.[11; 14; 15]  Additionally, 
evidence from studies have started to question the effectiveness of opioids in treating some types of 
pain, including osteoarthritis.[7]  For these reasons, national policies, guidelines and initiatives have 
been developed and implemented over the last several years to help clinicians decrease opioid use and 
to employ multiple recommended risk mitigation strategies to reduce rates of associated harms.    
Recent studies have noted these initiatives to be effective with a downward trend in opioid prescribing 
in some settings.[6; 9; 13; 16; 20]  As an example, the Veterans Health Administration (VHA) launched a 
system−wide Opioid Safety Initiative (OSI) in October 2013 to educate prescribers about safer opioid 
prescribing practices, followed by a sustained organizational effort to attenuate opioid prescribing. A 
recent review of opioid prescription rates in the VHA system by Lin et al., 2017[9] delineated the 
decreasing trend in opioid prescribing since the OSI rollout.[9; 18]  Investigators demonstrated changes 
in both rates of prescribing as well as reductions in opioid doses (quantifiable as morphine equivalents) 
since the initiation of the OSI. 
Many studies, however, have not evaluated the impact of changing opioid prescribing practices on use 
of other non-opioid analgesics nor concurrent changes in reported pain intensity. Because of the 
continued public health threat opioids present, most studies have focused solely on opioid prescribing. 
[6; 8]  As policies and trends in opioid prescribing change, this will likely impact use of alternate 
analgesic options, especially non-opioid analgesic prescribing. These changes in practice may impact 
patient-reported pain intensity. Additionally, limitations of previous studies have assumed stable 
underlying populations, reporting total number of prescriptions by year or by month instead of 
calculating prescription rates.[1; 9; 11] Researchers commonly have not corrected for the varying length 
of each month (as much as 10%, 28-31 days) when calculating either counts or rates. 
The Evaluating Arthritis Analgesic Safety and Effectiveness (EAASE) project is an ongoing multicenter 
observational study evaluating the safety and effectiveness of analgesic medications prescribed to older 
veterans who have been diagnosed with osteoarthritis (1 IO1 HX000911-01A2). Using national data 
collected as part of this study, we had the opportunity to evaluate national trends in opioid and non-
opioid analgesic prescribing before and after the VHA OSI initiative. Our hypothesis is that with guidance 
limiting or decreasing use of opioid therapy, clinicians may increase prescribing of non-opioid analgesics.  
To determine if such changes in published analgesic policies and initiatives indirectly affected patient 
outcomes, concurrent pain intensity ratings will be evaluated.  
 ____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Trentalange, M., Runels, T., Bean, A., Kerns, R. D., Bair, M. J., Brody, A. A., Brandt, C. A., Hwang, U., & EAASE (Evaluating Arthritis Analgesic 
Safety and Effectiveness) Investigators. (2019). Analgesic prescribing trends in a national sample of older veterans with osteoarthritis: 
2012-2017. PAIN, 160(6), 1319–1326. https://doi.org/10.1097/j.pain.0000000000001509
Analgesic Prescribing Trends in Older Veterans with Osteoarthritis: 2012−2017 
Vanilla3_Pain_v16 Trentalange & Hwang      4/14/2020 2 
 
 
1. Methods 
2.1 Study Design and Data Sources 
We conducted a retrospective, interrupted time-series, segmented regression model of aggregated 
monthly national data available from the VHA Corporate Data Warehouse (CDW), a national repository 
of patient-level medical records.[17]  Data for this investigation were part of an observational study 
evaluating the safety and effectiveness of analgesics in older veterans with arthritis of the knee or hip. 
Outpatient prescription and pain intensity ratings and demographic covariate data from VHA CDW 
files[17] included name of analgesic and prescription release date, as well as any documented pain 
intensity ratings. Data was then aggregated monthly over a five-year study period and prescribing rates 
and summary pain intensity ratings calculated for entry into segmented regression models controlled for 
sociodemographic characteristics. Study protocols were approved by the VA Central Institutional Review 
Board (VA Central IRB Study 13-31, 1 I01 HX000911−01A2, IIR 12-106).  
2.2 Veterans Health Administration (VHA) Opioid Safety Initiative 
To study the overall trends in analgesic prescribing and the impact of a guideline-based analgesic safety 
initiative, total number of analgesic prescriptions and pain intensity ratings were evaluated in the 2 
years prior to and 3 years after the VHA OSI. The OSI was a national VHA clinical initiative to promote 
safe opioid-related prescribing that completed rollout to all VHA facilities in October 2013.[9; 18]  
2.3 Subjects 
A national sample of all VHA patients ≥50 years of age from January 1, 2012 – December 31, 2016, 
diagnosed with osteoarthritis of the knee and/or hip: ICD9: 715.15, 715.16, 715.25,715.26, 715.35, 
715.36, 715.95, 715.96; ICD10: M16.0, M16.1, M16.10, M16.11, M16.12, M16.2, M16.3, M16.30, 
M16.31, M16.32, M16.4, M16.5, M16.50, M16.51, M16.52, M16.6, M16.7, M16.9, M17, M17.0, M17.1, 
M17.10, M17.11, M17.12, M17.2, M17.3, M17.30, M17.31, M17.32, M17.4, M17.5, M17.9, M13.15, 
M13.151, M13.152, M13.159, M13.16, M13.161, M13.162, M13.169, M13.85, M13.851, M13.852, 
M13.859, M13.86, M13.861, M13.862, M13.869) was identified. Two outpatient visits or one inpatient 
encounter noting these ICD codes were required for inclusion. Sociodemographic variables included age 
(in years), gender, and race (white or non-white).  Rates used for outcomes and covariates are 
calculated as the monthly outcomes or covariates (numerator) divided by the number of unique 
veterans (denominator) in a given month. 
2.4 Outcomes 
Monthly rates of musculoskeletal analgesic prescriptions. All outpatient analgesic prescriptions for a 5-
year period (January 1, 2012 – December 31, 2016) were recorded and aggregated as counts by study 
month. Musculoskeletal analgesics were categorized as: opioids, NSAIDs, acetaminophen, and other 
study analgesic prescriptions. The denominator for the calculation of prescription rates was the number 
of unique patients ≥50 years of age, diagnosed with osteoarthritis of the knee or hip in a given month 
during the study period. Outcomes were adjusted for sociodemographic covariates, age, gender, and 
race. 
Opioids were defined as all opioid agonists including tramadol and their fixed non-opioid combinations 
with a few exceptions. Excluded were opioid and non−opioid cough preparations. NSAIDs included 
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celecoxib, diclofenac, etodolac, ibuprofen, indomethacin, ketoprofen, ketorolac, meloxicam, naproxen, 
piroxicam, salicylate, sulindac, and tolmetin. NSAIDs and acetaminophen were counted as separate 
prescriptions when used as single agents but not when in combination with opioids. Other study 
analgesics included menthol with and without salicylate, capsaicin, and local anesthetics. 
 
Pain intensity ratings are collected as part of routine outpatient clinical care in the VHA. This is usually 
documented as “the presence and intensity of pain” with responses provided by veterans in response to 
the question, “Please rate your pain right now on a 0 (no pain) to 10 (worst pain imaginable) scale. 
Following recommendations for optimal distributions and best fitting models when using pain score 
data, we followed recommendations by Goulet et.al.[4]  Only non-missing pain intensity ratings were 
included in analyses (i.e., missing was not counted as no or “zero” pain. Outpatient pain intensity ratings 
(excluding those from inpatient encounters) during the same study period were collected and 
summarized following recommended calculations for optimal model fit for zero-inflated Poisson 
distributions[4]: percentage of those reporting pain (0=no pain or 1=any pain), and the mean pain 
intensity rating of those reporting pain (rating, range 1−10 highest).  
2.5 Analysis 
Analyses followed a similar approach to that of Lin et.al. that modeled VHA high-dose opioid therapy 
and concurrent benzodiazepine prescriptions [9; 19]: segmented regression analyses of interrupted time 
series.  
All variables were examined for missing values and for appropriate distributions and summarized as 
mean and standard deviations for continuous and percentages for categorical measures.  
For the evaluation of pain intensity ratings, only outpatient ratings were used. A total of 10,350,959 
separate outpatient pain intensity ratings over the 5−year period were summarized as monthly values: 
proportion of those reporting pain (0 v. 1−10) and mean of those reporting pain (1−10 scale). Pain 
intensity ratings were also summarized as percent reporting mild (1-3), moderate (4-6), and severe (7-
10) pain. As common to all observational studies involving pain ratings, participants having more pain 
would more likely receive both stronger medication as well as more frequent appointments and 
assessments of pain intensity. However, these are recognized limitations of using observational data. 
Distributions were compared to the results of previous VHA system-wide analysis of pain score 
distributions[4] to validate the consistency of pain intensity ratings over time. 
The sample sociodemographic characteristics were examined. Raw counts for each category of study 
analgesic prescriptions (Total Study Analgesics, Opioid, NSAID, Other Study Analgesics, and 
Acetaminophen) were computed for each month.  These counts were standardized by dividing by the 
number of days in each month and then multiplied by the length of an average month (365.25/12=30.44 
days) and rounded to a whole number. Raw and standardized counts were examined and graphed. 
Finally, rates were calculated as follows: the number of prescriptions of each analgesic type within a 
standard month was divided by the number of unique patients (50+ years of age and meeting the 
diagnostic criteria) for the entire VHA within that month and multiplied by 100 to achieve a standardized 
monthly rate in mean prescriptions per 100 person−months.  
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For analgesic prescribing, Poisson regression was performed to model the standardized monthly 
prescription count (offset by the log [number of unique patients in that month]). All models exhibited 
highly significant over−dispersion and required negative binomial regression methods. 
Subsequently, negative binomial regression models were performed with the following variables: 
sociodemographic covariates (mean age [years], gender [% male], race [% white]); time (in months) for 
overall model linear slope; an indicator variable for OSI (pre or post) or step; and an interaction term 
between time and the indicator variable for OSI implementation to assess the possible change in slope 
(Δβ). A significant step term would signify a sharp increase or decrease – a step change − in prescribing 
associated with the OSI. Of note, the changes in slope (interaction term), slope change, (Δβ) from the 
pre- to post-OSI periods are of more substantive interest in demonstrating the effect of the OSI 
intervention. 
Autocorrelation was investigated using several methods (harmonic terms and ACF/PACF graphs). 
Because of the lack of consistent autocorrelation, we ultimately decided to use Poisson-family models 
that resulted in best fit with negative-binomial models (see below response) with no adjustments for 
autocorrelation/seasonality.  
Finally, pain intensity ratings were analyzed similarly with covariate-adjusted linear regression. Because 
pain intensity ratings typically conform to a zero−inflated Poisson, negative binomial distribution, or a 
hurdle Poisson/negative binomial distribution[4], the monthly average ratings were summarized by two 
complementary methods: proportion reporting pain (1−10 v. 0), and mean pain intensity rating for those 
reporting pain (1−10). All models were additionally adjusted for the same three covariates: mean age 
(years), gender (% male), race (% white). As with the negative binomial models, a step change would 
indicate an increase or decrease in pain intensity ratings associated with the OSI, while significant 
interaction term or change in slope would signal an increasing or decreasing trend in the level of pain 
post-OSI compared to pre-OSI. In addition, the percent of mild (1-3), moderate (4-6), and severe (7-10) 
pain were analyzed and graphed as described above, multivariable linear regression. 
Effect sizes for each of the prescription and pain intensity models were determined as follows. The 
predicted values and 95% confidence intervals for the end of the study (month 60, December 2016) was 
calculated from both the pre-OSI model and the full (pre-/post-OSI) model. These separate estimates 
were used to calculate the percent difference between the two prediction points with the pre-OSI 
prediction as the reference. A contrast was then performed for the pre/post-OSI model to decide 
significance (Hochberg adjusted) of these differences. The resulting predicted lines for both models 
were graphed along with unadjusted rates for comparison. 
2.6 Sample Size and Probability Adjustments 
Since the analyses involve counts in the thousands and denominators in the hundreds of thousands, like 
many previous studies of national databases, we did not perform an a priori sample size assessment[9]. 
Albeit, these aggregate summary measures (rates and means) comprise the datapoints for the analyses. 
We employed a quasi-experimental design (segmented regression of interrupted time series), in which it 
is generally accepted that more than a dozen points on either side of the “event”/inflection point of 
interest are enough to provide stable slope estimates. 
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Nevertheless, for the negative binomial sample size calculation, we performed a post hoc calculation for 
the total prescription rates results using R package, power.nb.test, showing that indeed, 12 values on 
each side of the inflection point is sufficient for 80% power (mu0=26.6, mu1=33.0, RR=1.011 (pre-/post-
OSI), theta=632, duration=1, α =0.05/two-sided). We had 22 pre-OSI and 38 post-OSI values. 
For the linear regression models, we used G*Power version 3.1.9.2 for overall R2: Multiple linear 
regression using α = 0.05, Power = 0.80, n predictors = 6, and effect size = .35 (large), a sample size of 46 
(data points) is required. N = 60 for our analysis. The range of effect sizes we saw for the linear 
regression (R2) was 0.29-0.91 (Table 2). 
Hochberg adjustments were applied to the resulting probabilities within the estimates for the negative 
binomial models and within the linear regression models.  
All analyses were performed with RStudio (Version 1.0.153, Boston, MA, USA) using R Version 3.4.2 and 
SAS version 9.4 (©SAS Institute, Cary, NC, USA).
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3.  Results  
During the study period, there were a total of 8,384,564 prescriptions written for 348,787 unique 
patients that met inclusion criteria (Table 1). Mean age for this cohort was 63.4 years (SD, 8.6) ranging 
from 50−104 years. Mean age for the cohort increased slightly over the study period from 64.3 to 66.3 
years (β=0.03, p <.0001 – not shown). Percent male gender (mean, 93.3%; range 92.4 – 93.6; β=−0.02, p 
<.0001 – not shown) and percent white race (mean, 69.2%; range 67.9 – 70.7; β=−0.04, p <.0001 – not 
shown) demonstrated small but significant decreases over the same period. The denominator for the 
monthly calculation of prescription rates was all veterans over 50 years old with the diagnosis of 
osteoarthritis of the knee or hip, including those who did not receive any analgesic prescriptions, in the 
study period (overall, 499,243 unique patients).  
3.1 Study Analgesics 
Total Study Analgesics (Tables 2 & 3, Figure 1): For total study analgesic prescriptions, there was a 
positive (increasing) trend pre-OSI (βtime=0.012, p=0.003). At the initiation of the OSI there was a 
significant step (0.319, p<.0001) as well as a pronounced negative change in slope (Δβ=−0.010, p<.0001). 
The post-OSI slope was not significantly different from zero or a flat trajectory. Total study analgesic 
prescriptions increased until the OSI inflection point, after which it displayed a flat trajectory (Figure 2). 
The effect size demonstrated a 30.6% (p<.001) drop in total analgesic prescribing compared to what 
would have been predicted (estimate, 95% CI) under the pre-OSI trend, 48.1 (41.9-55.2) v. 33.4 (31.3-
35.7) prescriptions/100 person-months. 
Opioids (Tables 2 & 3, Figure 1): Pre-OSI there was an increase in opioid prescribing (βtime=0.018, 
p<.0001) along with an increase in prescribing at about the time of the OSI (step change: 0.578, p 
<.0001). These trends were followed by a negative Δβ (−0.019, p<.0001). Figure 2 shows the pre-OSI 
increase in opioid prescribing followed by a pronounced sustained decrease post-OSI. Extrapolating the 
pre-OSI trend would predict 32.4 (28.3-37.1) prescriptions/100 person-months compared to 16.9 (15.7-
18.2) predicted under the full model (post-OSI), a significant -47.8% change (p<.001). 
NSAIDs (Tables 2 & 3, Figure 2): NSAIDs prescriptions were stable over the study period (βtime=0.002, 
p=0.743) showing no change in either step or slope change in the post-OSI period (Δβ=−0.001, p=0.743). 
Figure 3 illustrates an unchanging non-significant increase in NSAID prescribing over the entire study 
period without any associated perturbation related to the OSI. Similarly, the predicted lines from both 
the pre-OSI model and the full model show considerable overlap and no significant effect size changes, 
pre-OSI trend 10.7 (9.3-12.4) v. post-OSI trend 10.3 (9.7-11.0) with overlapping 95% confidence intervals 
and a small relative effect size (-3.7%, p=0.748). 
Other Study Analgesics (Tables 2 & 3, Figure 2): Other study analgesic prescriptions, increased modestly 
over the study period (βtime=0.012, p<0.0002). However, there was no step change (0.029, p=0.743) or 
change in slope in the post-OSI period (Δβ=−0.001, p=0.743). Other study analgesics showed increasing 
prescribing with no peri-OSI changes. End of study predictions resulted in only a -2.3% and non-
significant difference (p=0.748). 
Acetaminophen (Tables 2 & 3, Figure 2): Acetaminophen prescriptions demonstrated a flat trajectory 
over the study period (βtime=0.006, p=0.255). Although a small and modestly significant step decrease 
was noted (step=−0.145, p=0.004) and a very modest significant increase in slope in the post-OSI period 
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was noted (Δβ=0.005, p=0.047). The effect size calculation mirrored these results with modestly 
significant (10.5%, p=0.003) increase in acetaminophen prescribing at the end of the study compared to 
the pre-OSI trend, post-OSI: 2.1 (2.0-2.3) v 1.9 (1.6-2.2) prescriptions/100 person-months, respectively. 
3.2 Pain Intensity Measures 
Figure 4 illustrates the  pain intensity measures and their trajectories related to OSI implementation 
over the study period. 
Pain Intensity in those Reporting Pain (Tables 2 & 3, Figure 1): The slope of pain intensity in those 
reporting pain was unchanged over the study period (βtime= 0.003, p=0.613) and showed no changes 
related to OSI (step=0.015, p=0.963; Δβ=0.000, p=0.963). Effect size calculations showed a non-
significant 0.1% (p=0.870) increase in Pain Intensity in those reporting pain between the pre- and 
pre/post (full)-models. 
Percentage Reporting Pain (Tables 2 & 3, Figure 3): The percentage reporting pain increased gradually 
throughout the study period (βtime=0.089, p, p=0.038). As with the other pain intensity measures (Figures 
1 & 3), there were no step (0.926, p=0.271) or slope changes (Δβ=−0.029, p=0.662) associated with OSI. 
The effect size calculation for the end of study was non-significant (-1.9%, p=0.096). 
Percent Reporting Mild, Moderate, and Severe Pain (Tables 2 & 3, Figure 3): Breaking those Reporting 
Pain into Mild (1-3), Moderate (4-6), and Severe (7-10) pain revealed that there was a significant steady 
upward trend in those reporting Moderate Pain (βtime=0.046, p=0.047). Mild pain exhibited a small, non-
significant decrease over the study period (-0.016, p=0.729). Severe pain showed no significant slope 
over the study (0.059, p=0.109). The changes associated with OSI were small (all < 3% change), with no 
measure demonstrating any significant change associated with OSI (i.e., no significant step, Δβ, or effect 
size change).  
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4. Discussion 
4.1 Opioid and Non-opioid Analgesics 
This study described covariate-adjusted outpatient analgesic trends (opioid prescribing, non-opioid 
analgesic prescribing, and pain intensity ratings), to understand more comprehensively prescribing 
trends for an older group of OA patients before and after implementation of the VHA Opioid Safety 
Initiative. 
We found a rise in total analgesic prescriptions pre-OSI, driven primarily by increasing opioid 
prescriptions with lesser contributions from other study analgesics and acetaminophen. In the post-OSI 
era, there was a dramatic reduction in overall analgesic prescribing. This trend occurred because of the 
pronounced decrease in opioid prescribing in the post-OSI period which was partially compensated by 
increased prescriptions from the other categories, a general increase in other study analgesics 
prescribing over the entire study period and a modest increase in acetaminophen prescribing post-OSI. 
NSAID prescribing appeared to continue unchanged through the study period.  
The changes in these analgesic prescribing patterns did not parallel changes in overall reported pain 
intensity in this sample. Covariate-adjusted pain intensity measures (percentage reporting pain, but not 
pain intensity ratings in those reporting pain) show a clinically small, but significant steady increase over 
the entire study period. This was apparently due to a growing number of those experiencing moderate 
pain over the entire study period, compared to mild or severe pain. No step or slope changes associated 
with OSI were seen with any pain intensity measures. 
Previous studies have demonstrated inflection points [6; 9; 16] with opioid prescribing, albeit at 
different times. Kazanis et al.,[6] for example, using time-series forecasting models with both military 
and civilian data showed increasing and then decreasing prescriptions for opioids (inflection point about 
2011)[6]. We did not find a decrease in the 2011-2013 period as they did. Other studies have 
demonstrated that educational programs, state monitoring programs, and a “Best practices initiative” 
continue to be effective in reducing opioid prescribing.[16] Our findings mirrored those of Lin et al., 
2017[9] using VHA data demonstrating the increase and subsequent decrease in opioid prescribing pre-
post the 2013 OSI respectively.  
As the opioid epidemic continues to be a public health threat with risk of adverse outcomes from 
prescription opioids, clinicians will increasingly be challenged to balance adequately treating patient 
pain while limiting the use of opioid analgesics. As previously mentioned, other studies indict and 
challenge the benefits of opioids in various disease states, including osteoarthritis.[7] Findings from this 
study demonstrate that with programs to ensure safer opioid prescribing practices, there has been an 
effective reduction in the use of opioids but also a concurrent increase in the use of non-opioid analgesic 
alternative medications. . Acetaminophen showed a very modest increase in prescribing post-OSI. There 
continues to be a steady increase in other study analgesic use, but not one that is at a greater rate of 
increase than prior to the OSI. If these practice trends continue, there should be awareness and 
monitoring of the impact that the greater use these analgesic medications may have on safety, 
effectiveness, and clinical outcomes for the patients being treated.[10; 21]  Clinicians will need to be 
informed of the risks and benefits of these analgesic alternates in older patients. Future studies should 
evaluate the safety and effectiveness of not only opioid analgesic use, but also these alternate non-
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opioid analgesic medications that appear to be increasingly used, as indicated by this study, to treat pain 
in older persons.  
4.2 Limitations 
This study has several limitations. Data and results do not reflect causality as this was an observational 
study. In addition, findings from VHA data, particularly in this older subset, may not be generalizable to 
other health care settings and patient populations. While the emphasis was on evaluation of prescribing 
trends before and after OSI implementation, undoubtedly, concurrent national policies related to 
analgesic prescribing, as well as public awareness of risks, may have also impacted changes in 
prescribing trends. 
In this investigation, data on non-VHA prescribed medications and self-administration of over-the-
counter medications or alternative therapies were not available. We did not evaluate co-prescribing of 
sedative medications nor calculate the doses of prescribed opioids (as in morphine equivalent doses) 
but confined our analyses to prescription rates. Lastly, the presence of co-morbid medical (such as 
cancer or other terminal) and mental health conditions was assumed to be randomly distributed and 
stable over the study period. 
In the future, an interrupted time−series series analysis will be used to investigate seasonality, produce 
forecasts to compare with subsequent data, as well as execute a more comprehensive model to 
associate all the other non−opioid analgesic medications with opioid trends. 
4.3 Summary 
In conclusion, recent trends and opioid prescribing safety initiatives have been effective and as 
demonstrated by this and other studies; there are decreasing rates of opioid prescribing for older 
veterans with osteoarthritis of the knee and hip. These changes in decreased opioid prescribing are 
largely not compensated by the prescribing of other analgesic classes in these older patients. However, 
changes in analgesic prescribing do not appear to be associated with concurrent changes in reported 
pain intensity by older veterans with osteoarthritis. Future studies should investigate potential risks and 
benefits of these changing rates of opioid and non-opioid analgesic medications and the impact these 
have on patient safety and pain intensity outcomes.   
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Tables and Figures 
Figure Legends: 
Figure 1. EAASE National Cohort, Rates for All Study Analgesic Prescriptions (2012−2017). Opioid and 
non−opioid prescription classes and total analgesic prescriptions as rates (mean count/100 
person−months). Counts were adjusted according to the length of a standard month (365.25 
days/12=30.44 days) to account for the varying length of each month. 
Figure 2. EAASE National Cohort, Rates for Total Analgesic Prescriptions, Opioid Prescriptions, and 
Mean Pain Intensity Score for Those Reporting Pain (2012−2017). Rates and superimposed lines from 
multivariable negative binomial models for prescription rates and a multivariable linear regression 
model for Mean Pain Intensity including terms for slope, step change (pre-/post-OSI), and change in 
slope. Pre-OSI models and predicted values (dashed lines) include only term for slope. All models 
additionally adjusted for age (years), male gender (%), and white race (%).  
Figure 3. EAASE National Cohort, Rates for Nonsteroidal Anti−inflammatory Drugs (NSAIDs), Other 
Study Analgesics and Acetaminophen (2012−2017). Rates and superimposed lines from multivariable 
negative binomial models including terms for slope, step change (pre-/post-OSI), and change in slope. 
Pre-OSI models and predicted values (dashed lines) include only term for slope. All models additionally 
adjusted for age (years), male gender (%), and white race (%).  
Figure 4. EAASE National Cohort, Percent values for Pain Intensity Measures: Percentages Reporting 
Pain, Mild Pain (1-3), Moderate Pain (4-6), and Severe Pain (7-10)  (2012−2017). Monthly mean 
percentages and superimposed lines from multivariable linear regression models including terms for 
slope, step change (pre-/post-OSI), and change in slope. Pre-OSI models and predicted values (dashed 
lines) include only term for slope. All models additionally adjusted for age (years), male gender (%), and 
white race (%).  
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